Following several studies on unreported clinical trial results and a court ruling on the issue, the US Food and Drug Administration recently took its first enforcement action against a sponsor for failing to post its data on ClinicalTrials.gov. The move is compelling companies to respond to queries from the agency about missing data and is expected to result in more enforcement actions.
The FDA issued its first notice of noncompliance with clinical trial reporting requirements to Acceleron Pharma, Inc. The action...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?